International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Commentary: Biomarkers of Disease Progression in Psoriasis: Current State-of-the-Art

blog_-_commentary_-_chiricozzi

Andrea Chiricozzi, MD
Department of Translational
Medicine and Surgery
Rome, Italy

PUBLICATIONS

1. Biomarkers of Disease Progression in People with Psoriasis: A Scoping Review. Ramessur R, Corbett M, Marshall D, Acencio ML, Barbosa IA, et al. Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21627. Epub ahead of print. PMID: 35482474.

2. Combined Single-Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning. Liu J, Kumar S, Hong J, Huang ZM, et al. Front Immunol. 2022 Mar 2;13:835760. doi: 10.3389/fimmu.2022.835760. PMID: 35309349; PMCID: PMC8924042.

3. Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modelling. Soomro M, Stadler M, Dand N, et al. Arthritis Rheumatol. 2022 May 4. doi: 10.1002/art.42154. Epub ahead of print. PMID: 35507331.

Why these articles were chosen

In personalized care for patients, psoriasis biomarkers will be highly relevant. At present, various centers have investigated biomarkers and their clinical significance for psoriasis progression. We want to draw your attention to three recent publications, and we have asked an outstanding expert to provide his comments.

Commentary

Identifying biomarkers related to disease progression in psoriasis (PsO) represents a field of research that has been extensively explored. Clinical implications are dramatically relevant as the identification of biomarkers would help select those patients at risk of disease progression, defined as progression in disease severity and/or development of comorbidities, such as type II diabetes and arthritis (PsA).

Notwithstanding the efforts in identifying valuable candidates, no biomarkers are part of the routine practice as they are not supported by sufficient evidence. However, a scoping review1 analyzing 61 studies proposed a panel of 22 potential biomarkers of PsO progression, identified at the genomic, proteomic, and metabolomic levels. Most of them are involved in pathogenically relevant signaling pathways (i.e., IL-23/IL-17 pathway), antigen processing, and presentation (HLA-C*06:02, HLA-B*27, HLA-B*38, HLA-B*08), leucocyte recruitment (i.e., CXCL10) and activation (IL-13).

Eleven and fourteen candidates demonstrated potential biomarkers for disease severity and PsA development. A recent transcriptomic study attempted to identify additional potential biomarkers of PsA to facilitate early diagnosis via a machine-learning-based model.2 Overall, the study shed light on the differences between PsO and PsA in terms of circulating immune cell profile. Still, the machine-learning approach did not capture early or ephemeral biomarkers of disease progression in PsO patients who develop PsA.2 Other genetic risk factors predicting PsA development were investigated by Soomro M. et al.3 Their study proposed a novel susceptibility locus for PsA mapping on chromosome 22q11 and defined genes differentiating PsA from PsO (genes encoding members for NF- kB signaling and WNT signaling) through genome-wide meta-analyses. Nevertheless, the prediction model did not reveal any genomic risk factor for PsA, highlighting the modest performance of a risk model based on the currently available datasets.3 This finding confirmed the occurrence of multiple biases and methodological limitations in studies exploring the identification of biomarkers in psoriasis. Indeed, the ideal study is longitudinal in design, with a primary objective that should consist of the investigation of biomarkers related to disease progression. Information on key patient cohort characteristics (including participants’ ethnicity, age, psoriasis age-of-onset, and psoriasis subtypes) should be included. Confounding factors such as that ongoing therapies that could modify the course of disease and the accuracy in diagnosing comorbidities should be considered. These aspects were underlined by Ramessur R. et al., suggesting hints for designing and conducting future biomarker studies.1

Nowadays, a list of candidate biomarkers might be proposed, though they do not own sufficient evidence for clinical use without further validation. Thereby, identifying biomarkers predicting the risk of disease progression and/or development of comorbid conditions, in particular PsA, remains an important research question still unanswered.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Tags

Recent Posts

PASI 90 blog post with Dr. Maskin

Access to Biologics in Argentina: Rethinking Time to PASI 90

Blog Post - Psoriasis Hub

IPC Partners with Scientific Education Support to Create New Psoriasis and Psoriatic Arthritis Hub

Blog -Expert Insights-Erica-Alba (1)

Monkeypox Symptoms, Treatment, Prevention, and Impact on Psoriasis Patients

Also Read

Filip Rob Commentary graphic
deucravacitinib

Commentary: Deucravacitinib Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-week, Randomized, Double-blinded, Placebo-controlled Phase 3 POETYK PSO-1 Trial

The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data of deucravacitinib were compared and contrasted with placebo and apremilast. The outcome of this comparative study lends support for the position of deucravacitinib in the spectrum of treatments for psoriasis.

Read More
Blog - Commentary - Alexander Egeberg - graphic
Secukinumab

Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis

Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the complexity of the real world? Alexander Egeberg, MD, PhD, DMSc, discusses a present study that examined drug survival among 16,122 treatment courses of biologic therapy with either guselkumab, ixekizumab, secukinumab, ustekinumab, or adalimumab, using United Kingdom registry data.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.